Elise D. Bowman

Elise D. Bowman

Auto-generated profile, based on publicly available information

Elise D. Bowman

Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
ZCZhaoxiang Cai
Zhaoxiang Cai
EBEmma Boys
Emma Boys
ZNZainab Noor
Zainab Noor
AAAdel T. Aref
Adel T. Aref
DXDylan Xavier
Dylan Xavier
RRRoger Reddel
Roger Reddel
Artificial intelligence applications in biomedicine face major challenges from data privacy requirements. To address this issue for clinically annotated tissue proteomic data, we developed a federated deep learning approach (ProCanFDL), training local models on simulated sites containing data from a pan-cancer cohort (n = 1,260) and 29 cohorts held behind private firewalls (n = 6,265), representing 19,930 replicate data-independent acquisition mass spectrometry runs. Local parameter updates were aggregated to build the global model, achieving a 43% performance gain on the hold-out test set (n = 625) in 14 cancer subtyping tasks compared with local models and matching centralized model performance. The approach’s generalizability was demonstrated by retraining the global model with data from two external, data-independent acquisition mass spectrometry cohorts (n = 55) and eight acquired by tandem mass tag proteomics (n = 832). ProCanFDL presents a solution for internationally collaborative machine learning initiatives using proteomic data, for example, for discovering predictive biomarkers or treatment targets while maintaining data privacy. Significance: A federated deep learning approach applied to human proteomic data, acquired using two distinct proteomic technologies from 40 tumor cohorts across eight countries, enabled accurate cancer histopathologic subtyping while preserving data privacy. This approach will enable the privacy-compliant development of large-scale proteomic artificial intelligence models, including foundation models, across institutions globally.

31 July 1990 in Biochemistry
Verified
Journal Article
Closed access
EBElise D. Bowman
Elise D. Bowman
MMMichael S. McQueney
Michael S. McQueney
JSJeffrey D. Scholten
Jeffrey D. Scholten
DDDebra Dunaway-Mariano
Debra Dunaway-Mariano

1 December 2018 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
PEPatricia Erickson
Patricia Erickson
LGLisa D. Gardner
Lisa D. Gardner
CLChristopher Loffredo
Christopher Loffredo
DGDiane Marie St. George
Diane Marie St. George
EBElise D. Bowman
Elise D. Bowman
BRBrid M. Ryan
Brid M. Ryan
Background: African Americans (AA) experience higher incidence and mortality of lung cancer as compared with European Americans (EA). Inflammation is associated with lung cancer, many aspects of which differ between AA and EA. We investigated whether use, frequency, and duration of the anti-inflammatory drug aspirin were associated with lung cancer risk and survival, separately among AA and EA populations. Methods: Using data from the Maryland Non–Small Cell Lung Cancer (NSCLC) Case–Control Study (1,220 cases [404 AA and 816 EA] and 1,634 controls [1,004 EA and 630 AA]), we estimated the adjusted odds ratios (OR) and hazard ratios (HR) with 95% confidence intervals (CI) of the associations between aspirin use and NSCLC risk and survival, respectively. Results: Any aspirin use (OR: 0.66; 95% CI, 0.49–0.89), daily use of ≥ 1 tablet (OR: 0.68; 95% CI, 0.50–0.90), and use for ≥ 3 years (OR: 0.61; 95% CI, 0.44–0.85) was associated with lower NSCLC risk only among men, even after adjustment for covariates including body mass index and global genetic ancestry. These variables were also associated with improved survival, but only among AA (HR: 0.64; 95% CI, 0.46–0.91; HR: 0.61; 95% CI, 0.42–0.90; and HR: 0.60; 95% CI, 0.39–0.92, respectively). Tylenol and other NSAIDs were either associated with elevated or no NSCLC risk. Conclusions: Aspirin use is associated with lower risk of NSCLC among men and improved survival among AA. Impact: Preventive regular aspirin use could be considered among men and AA.

5 June 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Purpose: Nonsmokers account for 10% to 13% of all lung cancer cases in the United States. Etiology is attributed to multiple risk factors including exposure to secondhand smoking, asbestos, environmental pollution, and radon, but these exposures are not within the current eligibility criteria for early lung cancer screening by low-dose CT (LDCT). Experimental Design: Urine samples were collected from two independent cohorts comprising 846 participants (exploratory cohort) and 505 participants (validation cohort). The cancer urinary biomarkers, creatine riboside (CR) and N-acetylneuraminic acid (NANA), were analyzed and quantified using liquid chromatography–mass spectrometry to determine if nonsmoker cases can be distinguished from sex and age-matched controls in comparison with tobacco smoker cases and controls, potentially leading to more precise eligibility criteria for LDCT screening. Results: Urinary levels of CR and NANA were significantly higher and comparable in nonsmokers and tobacco smoker cases than population controls in both cohorts. Receiver operating characteristic analysis for combined CR and NANA levels in nonsmokers of the exploratory cohort resulted in better predictive performance with the AUC of 0.94, whereas the validation cohort nonsmokers had an AUC of 0.80. Kaplan–Meier survival curves showed that high levels of CR and NANA were associated with increased cancer-specific death in nonsmokers as well as tobacco smoker cases in both cohorts. Conclusions: Measuring CR and NANA in urine liquid biopsies could identify nonsmokers at high risk for lung cancer as candidates for LDCT screening and warrant prospective studies of these biomarkers.

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
Box plots showing the distribution of CR and NANA urinary metabolite levels in the (A) exploratory cohort and (B) validation cohort were quantitatively measured by UPLC–MS/MS in the study participants. Kruskal–Wallis ANOVA; posthoc multiple comparisons, ****P < 0.0001; **P < 0.01. LCC, lung cancer cases; x͂ = median.

15 August 2024
Verified
Other
Open access
BDBhavik Dalal
Bhavik Dalal
TTTakeshi Tada
Takeshi Tada
DPDaxeshkumar P Patel
Daxeshkumar P Patel
SPSharon R. Pine
Sharon R. Pine
MKMohammed Khan
Mohammed Khan
CHCurtis C. Harris
Curtis C. Harris
The diagnostic efficiency of models in non-smoking exploratory and validation cohorts. LCC, Lung cancer cases; PC, Population controls; AUC, area under the curve; CI, confidence interval; SN, Sensitivity; SP, Specificity; NPV, negative predictive values; PPV, positive predictive values; CR, Creatine riboside; NANA- N-acetyl neuraminic acid.